Detalhe da pesquisa
1.
Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma.
Blood
; 141(20): 2470-2482, 2023 05 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36821767
2.
Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations.
Blood
; 142(10): 865-877, 2023 09 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37300386
3.
Outcomes after chimeric antigen receptor T-cell therapy across large B-cell lymphoma subtypes.
Haematologica
; 2024 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38572567
4.
A novel predictive algorithm to personalize autologous T-cell harvest for chimeric antigen receptor T-cell manufacture.
Cytotherapy
; 25(3): 323-329, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36513573
5.
Release Assays and Potency Assays for CAR T-Cell Interventions.
Adv Exp Med Biol
; 1420: 117-137, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37258787
6.
A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience.
Br J Haematol
; 198(3): 492-502, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35485402
7.
Cardiovascular Events Associated with Chimeric Antigen Receptor T Cell Therapy: Cross-Sectional FDA Adverse Events Reporting System Analysis.
Biol Blood Marrow Transplant
; 26(12): 2211-2216, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32966880
8.
Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo- or immunotherapy.
Br J Haematol
; 191(2): 194-206, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32678948
9.
RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature.
Blood
; 132(20): 2154-2165, 2018 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30181174
10.
Neurotoxicity-CAR T-cell therapy: what the neurologist needs to know.
Pract Neurol
; 20(4): 285-293, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32503897
11.
Manufacturing chimeric antigen receptor T cells: issues and challenges.
Cytotherapy
; 21(3): 327-340, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30685216
12.
Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial.
Br J Haematol
; 196(4): e33-e37, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34636043
13.
Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial.
Br J Haematol
; 193(3): e19-e22, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33715154
14.
Trafficking of CAR T cells to sites of subclinical leukaemia cutis.
Lancet Oncol
; 21(3): e179, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32135121
15.
Response to 'Impact of immunosuppression on mortality in critically ill COVID-19 patients'.
Br J Haematol
; 191(3): 505-506, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33103782
16.
Current Treatment Options for Renal Cell Carcinoma: Focus on Cell-Based Immunotherapy.
Cancers (Basel)
; 16(6)2024 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38539542
17.
Mucormycosis after CD19 chimeric antigen receptor T-cell therapy: results of a US Food and Drug Administration adverse events reporting system analysis and a review of the literature.
Lancet Infect Dis
; 24(4): e256-e265, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38310904
18.
High pretreatment disease burden as a risk factor for infectious complications following CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma.
Hemasphere
; 8(1): e29, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38434533
19.
Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy.
J Clin Oncol
; 42(2): 205-217, 2024 Jan 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37874957
20.
Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access scheme.
Blood Cancer J
; 14(1): 66, 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38622139